Title
Efficacy and Safety of Intravitreal Aflibercept Treat-and-Extend Regimens in the
ALTAIR study: 96-Week Outcomes in the Polypoidal Choroidal Vasculopathy
Subgroup

Authors

Annabelle A. Okada,¹ Kanji Takahashi,² Masahito Ohji,³ SungChul Charles Moon,⁴ Tobias
Machewitz,⁵ Koji Sasaki,⁶ on behalf of the ALTAIR study investigators

¹Department of Ophthalmology, Kyorin University School of Medicine, Tokyo, Japan
²Department of Ophthalmology, Kansai Medical University, Osaka, Japan
³Department of Ophthalmology, Shiga University of Medical Science, Shiga, Japan
⁴Department of Medical Affairs & Pharmacovigilance, Bayer AG, Berlin, Germany
⁵Department of Research & Development, Bayer AG, Berlin, Germany
⁶Department of Medical Affairs & Pharmacovigilance, Bayer Yakuhin Ltd., Osaka, Japan

Corresponding author
Annabelle A. Okada
Department of Ophthalmology
Kyorin University School of Medicine
6-20-2, Shinkawa
Mitaka, Tokyo, 181-8611
Japan
Email: aokada@e23.jp
Supplementary material

Supplementary Figure 1. Length of the last actual treatment interval in the PCV subgroup up to Week 96

Supplementary Figure 2. Mean change in BCVA (ETDRS letters) from baseline to Week 96 in the PCV subgroup

Supplementary Figure 3. Change in BCVA from Week 88 to Week 96 in the PCV subgroup (post hoc analysis)

Supplementary Figure 4. Absolute CRT for patients in the PCV subgroup between baseline and Week 96

Supplementary Figure 5. Polyp status in the PCV subgroup from baseline to Week 96 (post hoc analysis)

List of investigators

List of Institutional Review Boards
Supplementary Figure 1. Length of the last actual treatment interval in the PCV subgroup up to Week 96

Full analysis set. Note: The last actual treatment interval was defined as the interval between the last two injections.

2W/4W, 2-/4-week adjustment; IVT-AFL, intravitreal aflibercept; PCV, polypoidal choroidal vasculopathy.
Supplementary Figure 2. Mean change in BCVA (ETDRS letters) from baseline to Week 96 in the PCV subgroup

Full analysis set. Last observation carried forward.
2W/4W, 2-/4-week adjustment; BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; IVT-AFL, intravitreal aflibercept; PCV, polypoidal choroidal vasculopathy.
Supplementary Figure 3. Change in BCVA from Week 88 to Week 96 in the PCV subgroup (post hoc analysis)

Full analysis set. Last observation carried forward.
2W/4W, 2-/4-week adjustment; BCVA, best-corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; IVT-AFL, intravitreal aflibercept; PCV, polypoidal choroidal vasculopathy.
**Supplementary Figure 4.** Absolute CRT for patients in the PCV subgroup between baseline and Week 96

Mean CRT:
IVT-AFL-2W: baseline, 400; Week 4, 291; Week 8, 259; Week 16, 275; Week 24, 263; Week 32, 256; Week 40, 257; Week 48, 258; Week 52, 251; Week 56, 254; Week 64, 254; Week 72, 252; Week 80, 251; Week 88, 255; Week 96, 251.
IVT-AFL-4W: baseline, 372; Week 4, 280; Week 8, 254; Week 16, 254; Week 24, 258; Week 32, 288; Week 40, 280; Week 48, 288; Week 52, 260; Week 56, 275; Week 64, 267; Week 72, 276; Week 80, 267; Week 88, 259; Week 96, 263.

Full analysis set. Last observation carried forward.

Boxes show the IQR (25% to 75%). The center line of the box and “+” show median and mean values, respectively. The top and bottom of the vertical bars show the maximum and minimum values (where values were within the range of 1.5 IQR); the values that exceed the range of 1.5 IQR were defined as outliers and are shown outside of the vertical bars as an “x.”

2W/4W, 2-/4-week adjustment; CRT, central retinal thickness; IQR, interquartile range; IVT-AFL, intravitreal aflibercept; PCV, polypoidal choroidal vasculopathy.
**Supplementary Figure 5.** Polyp status in the PCV subgroup from baseline to Week 96 (post hoc analysis)

Full analysis set. Last observation carried forward. Note: Polyp diagnosis by ICGA was at the discretion of the investigator. ‘Not available’ indicates that data were not available.

2W/4W, 2-/4-week adjustment; ICGA, indocyanine green angiography; IVT-AFL, intravitreal aflibercept; PCV, polypoidal choroidal vasculopathy; W, week.
List of study Investigators
Masahito Ohji
Tsukasa Hanemoto
Tatsushi Kaga
Takeya Kouno
Hirokuni Kitamei
Shinpei Sato
Kanji Takahashi
Ryoji Yanai
Eiichi Uchio
Kazunori Miyata
Yoshihiro Wakabayashi
Takatoshi Maeno
Tsutomu Yasukawa
Masayuki Horiguchi
Tetsuya Nishimura
Akiteru Kawahara
Yasuo Kurimoto
Kenichi Murai
Namie Kobayashi
Wataru Kimura
Eiko Matsushita
Tomohiro Iida
Kanako Yasuda
Masahiro Miura
Annabelle Ayame Okada
Ryusaburo Mori
Atsushi Sugiyama
Yasu Ito
Daisaku Kimura
Kei Nakai
Chota Matsumoto
Shinobu Takeuchi
Kishiko Okoshi
Yoshihisa Nuno
Yohei Nomoto
Toshio Mori
Muneyasu Takeda
Noriko Yoshida
Mio Hosokawa
Kohei Sonoda
List of Institutional Review Boards
Kozawa Eye Hospital and Diabetes Center
Japan Community Healthcare, Organization Chukyo Hospital
Osaka City University Hospital
Social care corporation Shuho-kai, Otsuka Eye Hospital
Yokohama City University Medical Center
Kansai Medical University Hospital
Yamaguchi University Hospital
Fukuoka University Hospital
Miyata Eye Hospital
Tokyo Medical University Hospital
Toho University Sakura Medical Center
Nagoya City University Hospital
Fujita Health University Hospital
Shiga University of Medical Science Hospital
Kansai Medical University Medical Center
University of Miyazaki Hospital
Kobe City Medical Center General Hospital
Iwate Medical University Hospital
Southern Tohoku Ophthalmic Clinic
Kimura Eye and Internal Medicine Hospital
Kochi Medical School Hospital
Tokyo Women's Medical University Hospital
Tokyo Medical University Hachioji Medical Center
Sapporo Katoh Ophthalmology Clinic
Tokyo Medical University Ibaraki Medical Center
Kyorin University Hospital
Nihon University Hospital
University of Yamanashi Hospital
Daiyukai Health System Daiyukai Clinic
Takatsuki Red Cross Hospital
Yodogawa Christian Hospital
Kindai University Hospital
Takeuchi Ophthalmology Clinic
St. Luke's International Hospital
JCHO Shimonoseki Medical Center
Asahi General Hospital
Iida Municipal Hospital
Soen-Muneyasu Eye Clinic
Shinshu University Hospital
Okayama University Hospital
Kyushu University Hospital